Document and Entity Information

3 Months Ended

Mar. 31, 2016

Apr. 27, 2016

Document Documentand Entity Information [Abstract]

Entity Registrant Name

SAFEGUARD SCIENTIFICS INC

Entity Central Index Key

0000086115

Current Fiscal Year End Date

--12-31

Entity Filer Category

Accelerated Filer

Document Type

10-Q

Document Period End Date

Mar. 31, 2016

Document Fiscal Year Focus

2016

Document Fiscal Period Focus

Q1

Amendment Flag

false

Entity Common Stock, Shares Outstanding

20,153,261

Trading Symbol

SFE

CONSOLIDATED BALANCE SHEETS (USD $)

In Thousands, unless otherwise specified

Mar. 31, 2016

Dec. 31, 2015

Current Assets:

Cash and cash equivalents

$ 28,163

$ 32,838

Marketable securities

10,936

31,020

Prepaid expenses and other current assets

5,159

5,810

Total current assets

44,258

69,668

Property and equipment, net

2,087

2,145

Ownership interests in and advances to partner companies

182,851

171,601

Loan participations receivable

2,627

2,649

Long-term marketable securities

3,250

9,743

Other assets

1,037

Total Assets

236,110

256,843

Current Liabilities:

Accounts payable

220

290

Accrued compensation and benefits

1,748

3,338

Accrued expenses and other current liabilities

3,315

2,789

Total current liabilities

5,283

6,417

Other long-term liabilities

4,030

3,965

Convertible senior debentures

51,344

50,956

Total Liabilities

60,657

61,338

Commitments and contingencies

Equity:

Preferred stock, $0.10 par value; 1,000 shares authorized

0

Common stock, $0.10 par value; 83,333 shares authorized; 21,573 shares issued at March 31, 2016 and December 31, 2015

2,157

Additional paid-in capital

818,271

817,434

Treasury stock, at cost; 1,420 and 993 shares at March 31, 2016 and December 31, 2015, respectively

(24,997)

(19,570)

Accumulated deficit

(619,722)

(604,270)

Accumulated Other Comprehensive Income (Loss), Net of Tax

(256)

(246)

Total Equity

175,453

195,505

Total Liabilities and Equity

$ 236,110

$ 256,843

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)

In Thousands, except Per Share data, unless otherwise specified

Mar. 31, 2016

Dec. 31, 2015

Statement of Financial Position [Abstract]

Preferred stock, par value

$ 0.10

Preferred stock, shares authorized

1,000

Common stock, par value

$ 0.10

Common stock, shares authorized

83,333

Common stock, shares issued

21,573

Treasury stock

1,420

993

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)

In Thousands, except Per Share data, unless otherwise specified

3 Months Ended

Mar. 31, 2016

Mar. 31, 2015

Income Statement [Abstract]

General and administrative expense

$ 5,228

$ 4,880

Operating loss

(5,228)

(4,880)

Other income (loss), net

0

(388)

Interest income

420

449

Interest expense

(1,149)

(1,122)

Equity loss

(9,495)

(8,662)

Net loss before income taxes

(15,452)

(14,603)

Income tax benefit (expense)

0

Net loss

$ (15,452)

$ (14,603)

Net loss per share:

Basic (in dollars per share)

$ (0.76)

$ (0.70)

Diluted (in dollars per share)

$ (0.76)

$ (0.70)

Weighted average shares used in computing loss per share:

Basic (in shares)

20,448

20,861

Diluted (in shares)

20,448

20,861

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)

In Thousands, unless otherwise specified

3 Months Ended

Mar. 31, 2016

Mar. 31, 2015

Cash Flows from Operating Activities:

Net cash used in operating activities

$ (5,840)

$ (6,481)

Cash Flows from Investing Activities:

Proceeds from sales of and distributions from companies

4,194

2,192

Acquisitions of ownership interests in companies

(17,073)

(14,129)

Advances and loans to companies

(7,119)

(8,338)

Repayment of advances and loans to companies

28

Increase in marketable securities

0

(9,337)

Decrease in marketable securities

26,602

8,815

Capital expenditures

(22)

(110)

Net cash provided by (used in) investing activities

6,610

(20,879)

Cash Flows from Financing Activities:

Issuance of Company common stock, net

0

549

Repurchase of Company common stock

(5,445)

0

Net cash provided by (used in) financing activities

(5,445)

549

Net change in cash and cash equivalents

(4,675)

(26,811)

Cash and cash equivalents at beginning of period

32,838

111,897

Cash and cash equivalents at end of period

$ 28,163

$ 85,086

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (USD $)

In Thousands, unless otherwise specified

Total

Accumulated Deficit [Member]

AOCI Attributable to Parent [Member]

Common Stock

Additional Paid-in Capital [Member]

Treasury Stock [Member]

Balance at Dec. 31, 2015

$ 195,505

$ (604,270)

$ (246)

$ 2,157

$ 817,434

$ (19,570)

Balance (in shares) at Dec. 31, 2015

993

Balance (in shares) at Dec. 31, 2015

21,573

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Net loss

(15,452)

Repurchase of common stock

(5,445)

Repurchase of common stock (in shares)

428

Issuance of restricted stock, net

48

30

18

Issuance of restricted stock, net (in shares)

(1)

Stock-based compensation expense

807

Other comprehensive loss

(10)

Balance at Mar. 31, 2016

$ 175,453

$ (619,722)

$ (256)

$ 2,157

$ 818,271

$ (24,997)

Balance (in shares) at Mar. 31, 2016

1,420

Balance (in shares) at Mar. 31, 2016

21,573

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Statement (USD $)

In Thousands, unless otherwise specified

3 Months Ended

Mar. 31, 2016

Mar. 31, 2015

Statement of Comprehensive Income [Abstract]

Net loss

$ (15,452)

$ (14,603)

Share of other comprehensive loss of equity method investments

(10)

0

Total comprehensive loss

$ (15,462)

$ (14,603)

General

The accompanying unaudited interim Consolidated Financial Statements of Safeguard Scientifics, Inc. (“Safeguard” or the “Company”) were prepared in accordance with accounting principles generally accepted in the United States of America and the interim financial statement rules and regulations of the SEC. In the opinion of management, these statements include all adjustments (consisting only of normal recurring adjustments) necessary for a fair presentation of the Consolidated Financial Statements. The interim operating results are not necessarily indicative of the results for a full year or for any interim period. Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations relating to interim financial statements. The Consolidated Financial Statements included in this Form 10-Q should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations included elsewhere in this Form 10-Q and with the Company’s Consolidated Financial Statements and Notes thereto included in the Company’s 2015 Annual Report on Form 10-K.

Retrospective Adoption of Accounting Guidance

In the first quarter of 2016, the Company adopted accounting guidance that required retrospective adjustment to previously issued financial statements. All prior period data presented in the Company's Consolidated Financial Statements reflect the retrospective adoption of this guidance.

In April 2015, the Financial Accounting Standards Board issued Accounting Standards Update ("ASU") No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. The ASU specifies that debt issuance costs related to a note shall be reported in the balance sheet as a direct reduction from the face amount of the note. The Company adopted the ASU in the first quarter of 2016. As a result of the adoption of ASU No. 2015-03, the Company reclassified its capitalized debt issuance costs previously recorded within Other assets to a contra-liability reducing Convertible senior debentures on the Consolidated Balance Sheets. The reclassification was $0.8 million as of December 31, 2015. The ASU had no effect on the Company's results of operations or liquidity.

Ownership Interests in and Advances to Partner Companies and Funds

Ownership Interests in and Advances to Partner Companies

The following summarizes the carrying value of the Company’s ownership interests in and advances to partner companies.



	March 31, 2016		December 31, 2015
	(Unaudited - In thousands)
Equity Method:
Partner companies	$	156,792	$	150,898
Private equity funds	869		942
	157,661		151,840
Cost Method:
Partner companies	5,774		5,024
Private equity funds	1,852		1,966
	7,626		6,990
Advances to partner companies	17,564		12,771
	$	182,851	$	171,601

In April 2016, the Company received $3.3 million associated with the achievement of the final performance milestone related to the December 2013 sale of ThingWorx, Inc. to PTC, Inc., resulting in a gain of $3.3 million which is included in Equity income (loss), net in the Consolidated Statements of Operations for the three months ended March 31, 2016. This amount was included in Prepaid expenses and other current assets in the Consolidated Balance Sheets as of March 31, 2016 as the Company was owed such amount as of March 31, 2016. In January 2016, the Company received $4.1 million in connection with the expiration of the escrow period related to the transaction, which was included in Prepaid expenses and other current assets in the Consolidated Balance Sheets as of December 31, 2015 as the Company had earned such amount as of December 31, 2015.

Acquisitions of Ownership Interests in Partner Companies and Funds

Acquisitions of Ownership Interests in Partner Companies

In March 2016, the Company funded $1.0 million of a convertible bridge loan to Hoopla Software, Inc. The Company had previously deployed an aggregate of $3.8 million in Hoopla. Hoopla provides cloud-based software that helps sales organizations inspire and motivate sales team performance. The Company accounts for its interest in Hoopla under the equity method.

In March 2016, the Company funded $0.5 million of a convertible loan to NovaSom, Inc. The Company had previously deployed an aggregate of $21.0 million in NovaSom. NovaSom is a medical device company focused on obstructive sleep apnea, specifically home testing with its FDA-cleared wireless device called AccuSom^® Home Sleep Test. The Company accounts for its interest in NovaSom under the equity method.

In March and January 2016, the Company deployed an aggregate of $4.0 million into Full Measure Education, Inc. The Company had previously deployed $4.0 million in Full Measure. Full Measure is a technology company dedicated to the higher education industry. The Company accounts for its interest in Full Measure under the equity method.

In January 2016, the Company funded $1.0 million of a convertible bridge loan to AppFirst, Inc. The Company had previously deployed an aggregate of $11.6 million in AppFirst. AppFirst's patented technology provides enterprises with continuous and complete visibility into all the applications and supporting resources in their IT ecosystem, regardless of infrastructure. The Company accounts for its interest in AppFirst under the equity method.

In January 2016, the Company deployed an additional $4.4 million into WebLinc, Inc. The Company had previously deployed an aggregate of $6.6 million in WebLinc. WebLinc is a commerce platform provider for fast growing online retailers. The Company accounts for its interest in WebLinc under the equity method.

In January 2016, the Company funded $2.0 million of a convertible loan to Spongecell, Inc. The Company had previously deployed an aggregate of $14.0 million in Spongecell. Spongecell is a creative technology company that allows brand advertisers to create personal connections on a global scale. The Company accounts for its interest in Spongecell under the equity method.

In January 2016, the Company deployed an additional $1.0 million into InfoBionic, Inc. The Company had previously deployed an aggregate of $9.5 million in InfoBionic. InfoBionic is an emerging digital health company focused on creating patient monitoring solutions for chronic disease management with an initial market focus on cardiac arrhythmias. The Company accounts for its interest in InfoBionic under the equity method.

In January 2016, the Company deployed an additional $7.5 million into Syapse, Inc. The Company had previously deployed $5.8 million in Syapse. Syapse is a software company that enables healthcare providers to deploy precision medicine programs. The Company accounts for its interest in Syapse under the equity method.

In January 2016, the Company funded $2.0 million of a convertible bridge loan to Clutch Holdings, Inc. The Company had previously deployed an aggregate of $12.3 million in Clutch. Clutch provides consumer management technology that delivers customer intelligence and consumer engagement solutions to premium brands. The Company accounts for its interest in Clutch under the equity method.

Fair Value Measurements

The Company categorizes its financial instruments into a three-level fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). If the inputs used to measure fair value fall within different levels of the hierarchy, the category level is based on the lowest priority level input that is significant to the fair value measurement of the instrument. Financial instruments recorded at fair value on the Company’s Consolidated Balance Sheets are categorized as follows:

Level 1—Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2—Include other inputs that are directly or indirectly observable in the marketplace.

Level 3—Unobservable inputs which are supported by little or no market activity.

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

The following table provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of March 31, 2016 and December 31, 2015:



	Carrying Value		Fair Value Measurement at March 31, 2016
	Carrying Value		Level 1		Level 2		Level 3
	(Unaudited - In thousands)
Cash and cash equivalents	$	28,163	$	28,163	$	—	$	—
Marketable securities—held-to-maturity:
Government agency bonds	$	614	$	614	$	—	$	—
Certificates of deposit	13,572		13,572		—		—
Total marketable securities	$	14,186	$	14,186	$	—	$	—



	Carrying Value		Fair Value Measurement at December 31, 2015
	Carrying Value		Level 1		Level 2		Level 3
	(Unaudited - In thousands)
Cash and cash equivalents	$	32,838	$	32,838	$	—	$	—
Marketable securities—held-to-maturity:
Government agency bonds	$	1,329	$	1,329	$	—	$	—
Certificates of deposit	39,434		39,434		—		—
Total marketable securities	$	40,763	$	40,763	$	—	$	—

As of March 31, 2016, $10.9 million of marketable securities had contractual maturities which were less than one year and $3.3 million of marketable securities had contractual maturities greater than one year. Held-to-maturity securities are carried at amortized cost, which, due to the short-term maturity of these instruments, approximates fair value using quoted prices in active markets for identical assets or liabilities defined as Level 1 inputs under the fair value hierarchy.

Convertible Debentures and Credit Arrangements

Convertible Senior Debentures

In November 2012, the Company issued $55.0 million principal amount of its 5.25% convertible senior debentures due 2018 (the "2018 Debentures"). The 2018 Debentures may be settled in cash or partially in cash upon conversion. Accordingly, the Company separately accounts for the liability and equity components of the 2018 Debentures. The carrying amount of the liability component was determined at the transaction date by measuring the fair value of a similar liability that does not have an associated equity component. The carrying amount of the equity component represented by the embedded conversion option was determined by deducting the fair value of the liability component from the initial proceeds of the 2018 Debentures as a whole. At March 31, 2016, the fair value of the $55.0 million outstanding 2018 Debentures was approximately $58.0 million, based on the midpoint of the bid and ask prices as of such date. At March 31, 2016, the carrying amount of the equity component was $6.4 million, the principal amount of the liability component was $55.0 million, the unamortized discount was $2.9 million, unamortized debt issuance costs were $0.7 million and the net carrying value of the liability component was $51.3 million. The Company is amortizing the excess of the face value of the 2018 Debentures over their carrying value over their term as additional interest expense using the effective interest method and recorded $0.3 million of such expense for the three months ended March 31, 2016 and 2015. The effective interest rate on the 2018 Debentures is 8.7%.

Credit Arrangements

The Company is party to a loan agreement with a commercial bank which provides it with a revolving credit facility in the maximum aggregate amount of $25.0 million in the form of borrowings, guarantees and issuances of letters of credit, subject to a $20.0 million sublimit. Actual availability under the credit facility is based on the amount of cash maintained at the bank as well as the value of the Company’s public and private partner company interests. This credit facility bears interest at the prime rate for outstanding borrowings, subject to an increase in certain circumstances. Other than for limited exceptions, the Company is required to maintain all of its depository and operating accounts at the bank. The credit facility, as amended December 29, 2015, matures on December 19, 2016. Under the credit facility, the Company provided a $6.3 million letter of credit expiring on March 19, 2019 to the landlord of CompuCom Systems, Inc.’s Dallas headquarters which was required in connection with the sale of CompuCom Systems in 2004. Availability under the Company’s revolving credit facility at March 31, 2016 was $18.7 million.

Stock-Based Compensation

Stock-based compensation expense was recognized in the Consolidated Statements of Operations as follows:



	Three months ended March 31,
	2016		2015
	(Unaudited - In thousands)
General and administrative expense	$	807	$	257
	$	807	$	257

The fair value of the Company’s option awards to employees was estimated at the date of grant using the Black-Scholes option-pricing model. The risk-free rate was based on the U.S. Treasury yield curve in effect at the end of the quarter in which the grant occurred. The expected term of stock options granted was estimated using the historical exercise behavior of employees. Expected volatility was based on historical volatility measured using weekly price observations of the Company’s common stock for a period equal to the stock option’s expected term.

At March 31, 2016, the Company had outstanding options that vest based on three different types of vesting schedules:



1)	performance-based;
2)	market-based; and
3)	service-based.

Performance-based awards entitle participants to vest in a number of awards determined by achievement by the Company of target capital returns based on net cash proceeds received by the Company on the sale, merger or other exit transaction of certain identified partner companies. Vesting may occur, if at all, once per year. The requisite service periods for the performance-based awards are based on the Company’s estimate of when the performance conditions will be met. Compensation expense is recognized for performance-based awards for which the performance condition is considered probable of achievement. Compensation expense is recognized over the requisite service periods using the straight-line method but is accelerated if capital return targets are achieved earlier than estimated. During the three months ended March 31, 2016 and 2015, the Company did not issue any performance-based options to employees. During the three months ended March 31, 2016 and 2015, no performance-based options vested. During the three months ended March 31, 2016 and 2015, no performance-based options were canceled or forfeited. The Company recorded compensation expense related to performance-based options of $0.2 million and $0.0 million for the three months ended March 31, 2016 and 2015, respectively. The maximum number of unvested shares at March 31, 2016 attainable under these grants was 453 thousand shares.

Market-based awards entitle participants to vest in a number of options determined by achievement by the Company of certain target market capitalization increases (measured by reference to stock price increases on a specified number of outstanding shares) over an eight-year period. During the three months ended March 31, 2016 and 2015, the Company did not issue any market-based options to employees. During the three months ended March 31, 2016 and 2015, no market-based options vested. During the three months ended March 31, 2016 and 2016, no market-based options were canceled or forfeited. There is no further expense to be recognized related to market-based options. Depending on the Company’s stock performance, the maximum number of unvested shares at March 31, 2016 attainable under these grants was 136 thousand shares.

All other outstanding options are service-based awards that generally vest over four years after the date of grant and expire eight years after the date of grant. Compensation expense is recognized over the requisite service period using the straight-line method. The requisite service period for service-based awards is the period over which the award vests. During the three months ended March 31, 2016 and 2015, the Company issued 1 thousand and 13 thousand service-based options, respectively, to employees. During the three months ended March 31, 2016 and 2015, 8 thousand and 6 thousand service-based options, respectively, were canceled or forfeited. The Company recorded compensation expense related to service-based options of $0.0 million and $0.1 million for the three months ended March 31, 2016 and 2015, respectively.

Performance-based stock units vest based on achievement by the Company of target capital returns based on net cash proceeds received by the Company on the sale, merger or other exit transaction of certain identified partner companies, as described above related to performance-based awards. Performance-based stock units represent the right to receive shares of the Company’s common stock, on a one-for-one basis. During the three months ended March 31, 2016 and 2015, the Company did not issue any performance-based stock units to employees. Under the 2015 and 2014 performance-based award plans, once performance-based stock units are fully vested, participants are entitled to receive cash payments based on their initial performance grant values as target capital returns described above are exceeded. At March 31, 2016, the liability associated with such potential cash payments was $0.0 million.

During the three months ended March 31, 2016 and 2015, the Company issued 5 thousand and 2 thousand deferred stock units, respectively, to non-employee directors for annual service grants or fees earned during the preceding quarter. Deferred stock units issued to directors in lieu of directors fees are 100% vested at the grant date; matching deferred stock units equal to 25% of directors’ fees deferred vest one year following the grant date or, if earlier, upon reaching age 65. Deferred stock units are payable in stock on a one-for-one basis. Payments related to the deferred stock units are generally distributable following termination of employment or service, death or permanent disability.

During the three months ended March 31, 2016 and 2015, the Company did not issue any restricted stock awards.

Total compensation expense for deferred stock units, performance-based stock units and restricted stock was $0.6 million and $0.2 million for the three months ended March 31, 2016 and 2015, respectively.

Income Taxes

The Company’s consolidated income tax benefit (expense) was $0.0 million for the three months ended March 31, 2016 and 2015. The Company has recorded a valuation allowance to reduce its net deferred tax asset to an amount that is more likely than not to be realized in future years. Accordingly, the benefit of the net operating loss that would have been recognized in the three months ended March 31, 2016 and 2015 was offset by changes in the valuation allowance. During the three months ended March 31, 2016, the Company had no material changes in uncertain tax positions.

Net Income (Loss) Per Share

Net Loss Per Share

The calculations of net loss per share were as follows:



	Three months ended March 31,
	2016			2015
	(Unaudited - In thousands, except per share data)
Basic:
Net loss	$	(15,452	)	$	(14,603	)
Weighted average common shares outstanding	20,448			20,861
Net loss per share	$	(0.76	)	$	(0.70	)

Diluted:
Net loss	$	(15,452	)	$	(14,603	)
Weighted average common shares outstanding	20,448			20,861
Net loss per share	$	(0.76	)	$	(0.70	)

Basic and diluted average common shares outstanding for purposes of computing net income (loss) per share includes outstanding common shares and vested deferred stock units (DSUs).

If a consolidated or equity method partner company has dilutive stock options, unvested restricted stock, DSUs or warrants, diluted net income (loss) per share is computed by first deducting the income attributable to the potential exercise of the dilutive securities of the partner company from net income (loss). Any impact is shown as an adjustment to net income (loss) for purposes of calculating diluted net income (loss) per share.

Diluted earnings per share for the three months ended March 31, 2016 and 2015 do not reflect the following potential shares of common stock that would have an anti-dilutive effect or have unsatisfied performance or market conditions:


•	At March 31, 2016 and 2015, options to purchase 1.1 million and 1.3 million shares of common stock, respectively, at prices ranging from $7.14 to $19.95 for both periods were excluded from the calculations.


•	At March 31, 2016 and 2015, unvested restricted stock, performance-based stock units and DSUs convertible into 0.7 million and 0.4 million shares of stock, respectively, were excluded from the calculations.


•	At March 31, 2016 and 2015, 3.0 million shares of common stock, representing the effect of the assumed conversion of the 2018 Debentures, were excluded from the calculations.

Operating Segments

As of March 31, 2016, the Company held interests in 29 non-consolidated partner companies which are included in the Healthcare and Technology segments. The Company’s active partner companies by segment were as follows as of March 31, 2016:



Healthcare
Partner Company	Safeguard Primary Ownership as of March 31, 2016	Accounting Method
AdvantEdge Healthcare Solutions, Inc.	40.1%	Equity
Aventura, Inc.	19.9%	Equity
Good Start Genetics, Inc.	29.6%	Equity
InfoBionic, Inc.	39.8%	Equity
Medivo, Inc.	34.5%	Equity
meQuilibrium	31.5%	Equity
NovaSom, Inc.	31.7%	Equity
Propeller Health, Inc.	24.5%	Equity
Putney, Inc.	28.2%	Equity
Syapse, Inc.	29.2%	Equity
Trice Medical, Inc.	27.7%	Equity
Zipnosis, Inc.	26.2%	Equity



Technology
Partner Company	Safeguard Primary Ownership as of March 31, 2016	Accounting Method
AppFirst, Inc.	34.2%	Equity
Apprenda, Inc.	29.5%	Equity
Beyond.com, Inc.	38.2%	Equity
Bridgevine, Inc.	17.1%	Cost
Cask Data, Inc.	34.2%	Equity
CloudMine, Inc.	30.1%	Equity
Clutch Holdings, Inc.	38.5%	Equity
Full Measure Education, Inc.	36.0%	Equity
Hoopla Software, Inc.	25.6%	Equity
Lumesis, Inc.	44.4%	Equity
MediaMath, Inc.	20.5%	Equity
Pneuron Corporation	35.4%	Equity
QuanticMind, Inc.	23.6%	Equity
Sonobi, Inc.	22.6%	Equity
Spongecell, Inc.	23.0%	Equity
Transactis, Inc.	24.3%	Equity
WebLinc, Inc.	38.0%	Equity

Results of the Healthcare and Technology segments reflect the equity income (loss) of their respective equity method partner companies, other income (loss) associated with cost method partner companies and the gains or losses on the sale of the interests in their respective partner companies.

Management evaluates the Healthcare and Technology segments’ performance based on net income (loss) which is impacted by the number of partner companies accounted for under the equity method, the Company’s voting ownership percentage in these partner companies and the net results of operations of these partner companies, any impairment charges and gain (loss) on the sale of the interests in equity and cost method partner companies.

Other Items include certain expenses which are not identifiable to the operations of the Company’s operating segments. Other Items primarily consist of general and administrative expenses related to corporate operations, including employee compensation, insurance and professional fees, including legal and finance, interest income, interest expense and other income (loss), equity income (loss) related to certain private equity fund ownership interests and income taxes. Other Items also include interest earned on mezzanine loans, gain (loss) on the mark-to-market of our warrant participations, and impairment on debt and equity participation interests in which the Company participates with Penn Mezzanine as well as equity income (loss) associated with the Company's interest in the management company and general partner of Penn Mezzanine, a mezzanine lender focused on lower middle-market, Mid-Atlantic companies. Penn Mezzanine is not making any new loans and has two remaining loans in which the Company has participating interests.

As of March 31, 2016 and December 31, 2015, all of the Company’s assets were located in the United States.

Segment assets in Other Items included primarily cash, cash equivalents, and marketable securities totaling $42.3 million and $73.6 million at March 31, 2016 and December 31, 2015, respectively.



	Three months ended March 31, 2016
	Healthcare			Technology			Total Segments			Other Items			Total
	(Unaudited - In thousands)
Operating loss	$	—		$	—		$	—		$	(5,228	)	$	(5,228	)
Equity income (loss)	(4,996		)	(4,500		)	(9,496		)	1			(9,495		)
Net loss	(4,996		)	(4,500		)	(9,496		)	(5,956		)	(15,452		)
Segment Assets:
March 31, 2016	57,351			126,043			183,394			52,716			236,110
December 31, 2015	53,332			119,442			172,774			84,069			256,843



	Three months ended March 31, 2015
	Healthcare			Technology			Total Segments			Other Items			Total
	(Unaudited - In thousands)
Operating loss	$	—		$	—		$	—		$	(4,880	)	$	(4,880	)
Other income (loss), net	(239		)	—			(239		)	(149		)	(388		)
Equity income (loss)	(4,042		)	(4,772		)	(8,814		)	152			(8,662		)
Net loss	(4,281		)	(4,772		)	(9,053		)	(5,550		)	(14,603		)

Commitments and Contingencies

The Company and its partner companies are involved in various claims and legal actions arising in the ordinary course of business. In the current opinion of the Company, the ultimate disposition of these matters will not have a material adverse effect on the Company’s consolidated financial position or results of operations, however, no assurance can be given as to the outcome of these actions, and one or more adverse rulings could have a material adverse effect on the Company’s consolidated financial position and results of operations or that of its partner companies. The Company records costs associated with legal fees as such services are rendered.

The Company had outstanding guarantees of $3.8 million at March 31, 2016 which related to one of the Company's private equity holdings.

Under certain circumstances, the Company may be required to return a portion or all the distributions it received as a general partner of a private equity fund (“clawback”). The maximum clawback the Company could be required to return due to its general partner interest is approximately $1.3 million, of which $1.0 million was reflected in Accrued expenses and other current liabilities and $0.3 million was reflected in Other long-term liabilities on the Consolidated Balance Sheets at March 31, 2016. The Company’s ownership in the fund is 19%. The clawback liability is joint and several; therefore the Company may be required to fund the clawback for other general partners should they default. The Company believes its potential liability due to the possibility of default by other general partners is remote.

In October 2001, the Company entered into an agreement with a former Chairman and Chief Executive Officer of the Company, to provide for annual payments of $0.65 million per year and certain health care and other benefits for life. The related current liability of $0.8 million was included in Accrued expenses and other current liabilities and the long-term portion of $2.2 million was included in Other long-term liabilities on the Consolidated Balance Sheet at March 31, 2016.

The Company provided a $6.3 million letter of credit expiring on March 19, 2019 to the landlord of CompuCom Systems, Inc.’s Dallas headquarters as required in connection with the sale of CompuCom Systems in 2004.

The Company has agreements with certain employees that provide for severance payments to the employee in the event the employee is terminated without cause or an employee terminates his employment for “good reason.” The maximum aggregate exposure under the agreements was approximately $3.0 million at March 31, 2016.

In June 2011, the Company's former partner company, Advanced BioHealing, Inc. (“ABH”) was acquired by Shire plc. Prior to the expiration of the escrow period in March 2012, Shire plc filed a claim against all amounts held in escrow related to the sale based principally upon a United States Department of Justice (“DOJ”) false claims act investigation relating to ABH. No further proceeds will be distributed to the Company or other former owners until the validity of such claims is determined. The Company presently views it as unlikely that it will receive any portion of such amount in the short- or long-term. In connection with the above-referenced investigation, in July 2015 the Company received a Civil Investigation Demand-Documentary Material from the DOJ regarding ABH and Safeguard’s relationship with ABH. Safeguard intends to cooperate with the investigation.

Equity

In July 2015, the Company's Board of Directors authorized the Company, from time to time and depending on market conditions, to repurchase up to $25.0 million of the Company's outstanding common stock. The Company repurchased 0.4 million shares at an aggregate cost of $5.4 million during the three months ended March 31, 2016.

Subsequent Events

In April 2016, Putney, Inc. was acquired by Dechra Pharmaceuticals Plc. The Company received cash proceeds of $58.2 million in connection with the transaction, excluding approximately $0.6 million which will be held in escrow until April 2017. The Company expects to recognize a gain of approximately $55.0 million in the three and six months ending June 30, 2016.

Ownership Interests in and Advances to Partner Companies and Funds (Tables)

Ownership Interests in and Advances to Partner Companies and Private Equity Funds

The following summarizes the carrying value of the Company’s ownership interests in and advances to partner companies.



	March 31, 2016		December 31, 2015
	(Unaudited - In thousands)
Equity Method:
Partner companies	$	156,792	$	150,898
Private equity funds	869		942
	157,661		151,840
Cost Method:
Partner companies	5,774		5,024
Private equity funds	1,852		1,966
	7,626		6,990
Advances to partner companies	17,564		12,771
	$	182,851	$	171,601

Fair Value Measurements (Tables)

Carrying Value and Fair Value of Certain Financial Assets and Liabilities Measured at Fair Value on Recurring Basis

The following table provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of March 31, 2016 and December 31, 2015:



	Carrying Value		Fair Value Measurement at March 31, 2016
	Carrying Value		Level 1		Level 2		Level 3
	(Unaudited - In thousands)
Cash and cash equivalents	$	28,163	$	28,163	$	—	$	—
Marketable securities—held-to-maturity:
Government agency bonds	$	614	$	614	$	—	$	—
Certificates of deposit	13,572		13,572		—		—
Total marketable securities	$	14,186	$	14,186	$	—	$	—



	Carrying Value		Fair Value Measurement at December 31, 2015
	Carrying Value		Level 1		Level 2		Level 3
	(Unaudited - In thousands)
Cash and cash equivalents	$	32,838	$	32,838	$	—	$	—
Marketable securities—held-to-maturity:
Government agency bonds	$	1,329	$	1,329	$	—	$	—
Certificates of deposit	39,434		39,434		—		—
Total marketable securities	$	40,763	$	40,763	$	—	$	—

Stock-Based Compensation (Tables)

Stock-Based Compensation Expense

Stock-based compensation expense was recognized in the Consolidated Statements of Operations as follows:



	Three months ended March 31,
	2016		2015
	(Unaudited - In thousands)
General and administrative expense	$	807	$	257
	$	807	$	257

Types of Vesting Schedules

At March 31, 2016, the Company had outstanding options that vest based on three different types of vesting schedules:



1)	performance-based;
2)	market-based; and
3)	service-based.

Net Income (Loss) Per Share (Tables)

Calculations of Net Loss Per Share

The calculations of net loss per share were as follows:



	Three months ended March 31,
	2016			2015
	(Unaudited - In thousands, except per share data)
Basic:
Net loss	$	(15,452	)	$	(14,603	)
Weighted average common shares outstanding	20,448			20,861
Net loss per share	$	(0.76	)	$	(0.70	)

Diluted:
Net loss	$	(15,452	)	$	(14,603	)
Weighted average common shares outstanding	20,448			20,861
Net loss per share	$	(0.76	)	$	(0.70	)

Operating Segments (Tables)

Active Partner Companies by Segment

The Company’s active partner companies by segment were as follows as of March 31, 2016:



Healthcare
Partner Company	Safeguard Primary Ownership as of March 31, 2016	Accounting Method
AdvantEdge Healthcare Solutions, Inc.	40.1%	Equity
Aventura, Inc.	19.9%	Equity
Good Start Genetics, Inc.	29.6%	Equity
InfoBionic, Inc.	39.8%	Equity
Medivo, Inc.	34.5%	Equity
meQuilibrium	31.5%	Equity
NovaSom, Inc.	31.7%	Equity
Propeller Health, Inc.	24.5%	Equity
Putney, Inc.	28.2%	Equity
Syapse, Inc.	29.2%	Equity
Trice Medical, Inc.	27.7%	Equity
Zipnosis, Inc.	26.2%	Equity



Technology
Partner Company	Safeguard Primary Ownership as of March 31, 2016	Accounting Method
AppFirst, Inc.	34.2%	Equity
Apprenda, Inc.	29.5%	Equity
Beyond.com, Inc.	38.2%	Equity
Bridgevine, Inc.	17.1%	Cost
Cask Data, Inc.	34.2%	Equity
CloudMine, Inc.	30.1%	Equity
Clutch Holdings, Inc.	38.5%	Equity
Full Measure Education, Inc.	36.0%	Equity
Hoopla Software, Inc.	25.6%	Equity
Lumesis, Inc.	44.4%	Equity
MediaMath, Inc.	20.5%	Equity
Pneuron Corporation	35.4%	Equity
QuanticMind, Inc.	23.6%	Equity
Sonobi, Inc.	22.6%	Equity
Spongecell, Inc.	23.0%	Equity
Transactis, Inc.	24.3%	Equity
WebLinc, Inc.	38.0%	Equity

Segment Data from Operations



	Three months ended March 31, 2016
	Healthcare			Technology			Total Segments			Other Items			Total
	(Unaudited - In thousands)
Operating loss	$	—		$	—		$	—		$	(5,228	)	$	(5,228	)
Equity income (loss)	(4,996		)	(4,500		)	(9,496		)	1			(9,495		)
Net loss	(4,996		)	(4,500		)	(9,496		)	(5,956		)	(15,452		)
Segment Assets:
March 31, 2016	57,351			126,043			183,394			52,716			236,110
December 31, 2015	53,332			119,442			172,774			84,069			256,843



	Three months ended March 31, 2015
	Healthcare			Technology			Total Segments			Other Items			Total
	(Unaudited - In thousands)
Operating loss	$	—		$	—		$	—		$	(4,880	)	$	(4,880	)
Other income (loss), net	(239		)	—			(239		)	(149		)	(388		)
Equity income (loss)	(4,042		)	(4,772		)	(8,814		)	152			(8,662		)
Net loss	(4,281		)	(4,772		)	(9,053		)	(5,550		)	(14,603		)

General (Details) (USD $)

In Millions, unless otherwise specified

Dec. 31, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Deferred finance costs, noncurrent, net

$ 0.8

Ownership Interests in and Advances to Partner Companies and Funds - Carrying Value (Detail) (USD $)

In Thousands, unless otherwise specified

Mar. 31, 2016

Dec. 31, 2015

Investments In And Advances To Affiliates [Line Items]

Equity method investments

$ 157,661

$ 151,840

Cost method investments

7,626

6,990

Advances to partner companies

17,564

12,771

Investments in and advance to affiliates, subsidiaries, associates, and joint ventures

182,851

171,601

Partner companies

Investments In And Advances To Affiliates [Line Items]

Equity method investments

156,792

150,898

Cost method investments

5,774

5,024

Private equity funds

Investments In And Advances To Affiliates [Line Items]

Equity method investments

869

942

Cost method investments

$ 1,852

$ 1,966

Ownership Interests in and Advances to Partner Companies and Funds - Narrative (Detail) (USD $)

3 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

Mar. 31, 2016

Mar. 31, 2015

Jan. 31, 2016

Thing Worx Inc

Mar. 31, 2016

Thing Worx Inc

Apr. 30, 2016

Subsequent Event

Thing Worx Inc

Investment [Line Items]

Proceeds from sale of business

$ 4,194,000

$ 2,192,000

$ 4,100,000

$ 3,300,000

Gain on sale of business

$ 3,300,000

Acquisitions of Ownership Interests in Partner Companies and Funds (Detail) (USD $)

3 Months Ended

48 Months Ended

3 Months Ended

54 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

37 Months Ended

3 Months Ended

17 Months Ended

3 Months Ended

47 Months Ended

3 Months Ended

21 Months Ended

3 Months Ended

18 Months Ended

3 Months Ended

34 Months Ended

Mar. 31, 2016

Mar. 31, 2015

Mar. 31, 2016

Hoopla Software, Inc.

Dec. 31, 2015

Hoopla Software, Inc.

Mar. 31, 2016

Novasom, Inc.

Dec. 31, 2015

Novasom, Inc.

Mar. 31, 2016

Full Measure

Dec. 31, 2015

Full Measure

Mar. 31, 2016

AppFirst, Inc.

Dec. 31, 2015

AppFirst, Inc.

Mar. 31, 2016

WebLinc

Dec. 31, 2015

WebLinc

Mar. 31, 2016

Spongecell

Dec. 31, 2015

Spongecell

Mar. 31, 2016

InfoBionic

Dec. 31, 2015

InfoBionic

Mar. 31, 2016

Syapse, Inc.

Dec. 31, 2015

Syapse, Inc.

Mar. 31, 2016

Clutch Holdings, LLC

Dec. 31, 2015

Clutch Holdings, LLC

Schedule of Equity Method Investments [Line Items]

Payments to acquire equity method investments

$ 17,073,000

$ 14,129,000

$ 3,800,000

$ 21,000,000

$ 4,000,000

$ 11,600,000

$ 4,400,000

$ 6,600,000

$ 14,000,000

$ 1,000,000

$ 9,500,000

$ 7,500,000

$ 5,800,000

$ 12,300,000

Convertible bridge loan

$ 1,000,000

$ 500,000

$ 1,000,000

$ 2,000,000

Fair Value Measurements - Carrying Value and Fair Value of Certain Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) (Fair Value, Measurements, Recurring, USD $)

In Thousands, unless otherwise specified

Mar. 31, 2016

Dec. 31, 2015

Level 1

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Cash and cash equivalents

$ 28,163

$ 32,838

Total marketable securities

14,186

40,763

Level 2

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Cash and cash equivalents

0

Total marketable securities

0

Level 3

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Cash and cash equivalents

0

Total marketable securities

0

Carrying (Reported) Amount, Fair Value Disclosure

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Cash and cash equivalents

28,163

32,838

Total marketable securities

14,186

40,763

Government agency bonds |
Level 1

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Total marketable securities

614

1,329

Government agency bonds |
Level 2

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Total marketable securities

0

Government agency bonds |
Level 3

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Total marketable securities

0

Government agency bonds |
Carrying (Reported) Amount, Fair Value Disclosure

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Total marketable securities

614

1,329

Certificates of deposit |
Level 1

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Total marketable securities

13,572

39,434

Certificates of deposit |
Level 2

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Total marketable securities

0

Certificates of deposit |
Level 3

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Total marketable securities

0

Certificates of deposit |
Carrying (Reported) Amount, Fair Value Disclosure

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Total marketable securities

$ 13,572

$ 39,434

Fair Value Measurements - Narrative (Detail) (USD $)

In Thousands, unless otherwise specified

Mar. 31, 2016

Dec. 31, 2015

Fair Value Disclosures [Abstract]

Marketable securities, current

$ 10,936

$ 31,020

Marketable securities, non current

$ 3,250

$ 9,743

Convertible Debentures and Credit Arrangements - Convertible Senior Debentures Narrative (Detail) (USD $)

3 Months Ended

Dec. 31, 2015

Mar. 31, 2016

Convertible Senior Debentures due 2018

Mar. 31, 2015

Convertible Senior Debentures due 2018

Nov. 30, 2012

Convertible Senior Debentures due 2018

Debt Instrument [Line Items]

Aggregate face value of convertible senior debentures

$ 55,000,000

$ 55,000,000.0

Interest rate on debentures

5.25%

Fair value of debentures outstanding

58,000,000

Gross carrying amount of equity component

6,400,000

Unamortized discount

2,900,000

Deferred finance costs, noncurrent, net

800,000

700,000

Carrying value of liability component

51,300,000

Amortization of debt discount (premium)

$ 300,000

Debt instrument, interest rate, effective percentage

8.70%

Convertible Debentures and Credit Arrangements - Credit Arrangements Narrative (Detail) (Credit Arrangements, USD $)

3 Months Ended

Mar. 31, 2016

Debt Instrument [Line Items]

Maximum aggregate amount of revolving credit facility in the form of borrowings, guarantees and issuances of letters of credit (subject to a $20 million sublimit)

$ 25,000,000.0

Sublimit facility attached on revolving credit facility

20,000,000

Amount available for borrowing under revolving credit facility

18,700,000

After Amendment

Debt Instrument [Line Items]

Credit facility maturity date

Dec. 19, 2016

Landlord Of Compu Com Systems Incs Dallas Headquarters

Debt Instrument [Line Items]

Letter of credit under the credit facility

$ 6,300,000

Letter of credit expiration date

Mar. 19, 2019

Stock-Based Compensation - Stock-Based Compensation Expense (Detail) (USD $)

In Thousands, unless otherwise specified

3 Months Ended

Mar. 31, 2016

Mar. 31, 2015

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

Stock-based compensation expense

$ 807

$ 257

General And Administrative Expenses

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

Stock-based compensation expense

$ 807

$ 257

Stock-Based Compensation - Narrative (Detail) (USD $)

In Millions, except Share data, unless otherwise specified

3 Months Ended

Mar. 31, 2016

Mar. 31, 2015

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Number of award vesting types

3

Cash liability for performance-based units

$ 0

Performance Shares

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Stock-based compensation expense

0.2

0

Stock-based compensation, maximum number of unvested shares

453,000

Market Based Awards

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Stock-based compensation, maximum number of unvested shares

136,000

Vesting period

8 years

Service Based Award

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Stock-based compensation expense

0

0.1

Vesting period

4 years

Expiration period

8 years

Options issued

1,000

13,000

Options, forfeitures in period

8,000

6,000

Deferred Stock Units

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Percentage of shares vested in lieu of directors fees at the grant date

100.00%

Portion of Director fees matched to deferred stock units

25.00%

Vesting period of deferred stock

1 year

Minimum age required for meeting directors fees deferred vest criteria

65

Deferred Stock Units |
Director

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Shares issued to non-employee individual

5,000

2,000

Deferred stock units, performance-based stock units and restricted stock

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Stock-based compensation expense

$ 0.6

$ 0.2

Income Taxes (Detail) (USD $)

In Thousands, unless otherwise specified

3 Months Ended

Mar. 31, 2016

Mar. 31, 2015

Income Tax Disclosure [Abstract]

Income tax benefit (expense)

$ 0

Net Income (Loss) Per Share - Calculations of Net Income (Loss) Per Share (Detail) (USD $)

In Thousands, except Per Share data, unless otherwise specified

3 Months Ended

Mar. 31, 2016

Mar. 31, 2015

Basic:

Net income (loss)

$ (15,452)

$ (14,603)

Weighted average common shares outstanding (in shares)

20,448

20,861

Net income (loss) per share (in dollars per share)

$ (0.76)

$ (0.70)

Diluted:

Net income (loss) attributable to parent, diluted

$ (15,452)

$ (14,603)

Weighted average common shares outstanding (in shares)

20,448

20,861

Net income (loss) per share (in dollars per share)

$ (0.76)

$ (0.70)

Net Income (Loss) Per Share - Narrative (Detail) (USD $)

In Millions, except Per Share data, unless otherwise specified

3 Months Ended

Mar. 31, 2016

Mar. 31, 2015

Stock Options

Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]

Share of common stock excluded from diluted net loss per share calculation

1.1

1.3

Shares of common stock at prices ranging, lower limit

$ 7.14

Shares of common stock at prices ranging, upper limit

$ 19.95

Deferred stock units, performance-based stock units and restricted stock

Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]

Share of common stock excluded from diluted net loss per share calculation

0.7

0.4

Convertible Senior Debentures due 2018

Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]

Share of common stock excluded from diluted net loss per share calculation

3.0

Operating Segments - Narrative (Detail) (USD $)

In Millions, unless otherwise specified

Mar. 31, 2016

Dec. 31, 2015

Segment Reporting Information [Line Items]

Non-consolidated partner companies

29

Other Items

Segment Reporting Information [Line Items]

Total assets included cash, cash equivalents, cash held in escrow, and marketable securities

$ 42.3

$ 73.6

Operating Segments - Active Partner Companies by Segment (Detail)

Mar. 31, 2016

Healthcare |
AdvantEdge Healthcare Solutions, Inc.

Schedule of Equity Method Investments [Line Items]

Ownership interest under equity method, percentage

40.10%

Healthcare |
Aventura

Schedule of Equity Method Investments [Line Items]

Ownership interest under equity method, percentage

19.90%

Healthcare |
Good Start Genetics, Inc.

Schedule of Equity Method Investments [Line Items]

Ownership interest under equity method, percentage

29.60%

Healthcare |
InfoBionic

Schedule of Equity Method Investments [Line Items]

Ownership interest under equity method, percentage

39.80%

Healthcare |
Medivo, Inc.

Schedule of Equity Method Investments [Line Items]

Ownership interest under equity method, percentage

34.50%

Healthcare |
meQuilibrium

Schedule of Equity Method Investments [Line Items]

Ownership interest under equity method, percentage

31.50%

Healthcare |
Novasom, Inc.

Schedule of Equity Method Investments [Line Items]

Ownership interest under equity method, percentage

31.70%

Healthcare |
Propeller

Schedule of Equity Method Investments [Line Items]

Ownership interest under equity method, percentage

24.50%

Healthcare |
Putney, Inc.

Schedule of Equity Method Investments [Line Items]

Ownership interest under equity method, percentage

28.20%

Healthcare |
Syapse, Inc.

Schedule of Equity Method Investments [Line Items]

Ownership interest under equity method, percentage

29.20%

Healthcare |
Trice

Schedule of Equity Method Investments [Line Items]

Ownership interest under equity method, percentage

27.70%

Healthcare |
Zipnosis

Schedule of Equity Method Investments [Line Items]

Ownership interest under equity method, percentage

26.20%

Technology |
AppFirst, Inc.

Schedule of Equity Method Investments [Line Items]

Ownership interest under equity method, percentage

34.20%

Technology |
Apprenda

Schedule of Equity Method Investments [Line Items]

Ownership interest under equity method, percentage

29.50%

Technology |
Beyond.com, Inc

Schedule of Equity Method Investments [Line Items]

Ownership interest under equity method, percentage

38.20%

Technology |
Bridgevine, Inc.

Schedule of Equity Method Investments [Line Items]

Ownership interest under cost method, percentage

17.10%

Technology |
Cask Data

Schedule of Equity Method Investments [Line Items]

Ownership interest under equity method, percentage

34.20%

Technology |
CloudMine

Schedule of Equity Method Investments [Line Items]

Ownership interest under equity method, percentage

30.10%

Technology |
Clutch Holdings, LLC

Schedule of Equity Method Investments [Line Items]

Ownership interest under equity method, percentage

38.50%

Technology |
Full Measure

Schedule of Equity Method Investments [Line Items]

Ownership interest under equity method, percentage

36.00%

Technology |
Hoopla Software, Inc.

Schedule of Equity Method Investments [Line Items]

Ownership interest under equity method, percentage

25.60%

Technology |
Lumesis, Inc.

Schedule of Equity Method Investments [Line Items]

Ownership interest under equity method, percentage

44.40%

Technology |
MediaMath, Inc.

Schedule of Equity Method Investments [Line Items]

Ownership interest under equity method, percentage

20.50%

Technology |
Pneuron

Schedule of Equity Method Investments [Line Items]

Ownership interest under equity method, percentage

35.40%

Technology |
QuanticMind, Inc.

Schedule of Equity Method Investments [Line Items]

Ownership interest under equity method, percentage

23.60%

Technology |
Sonobi

Schedule of Equity Method Investments [Line Items]

Ownership interest under equity method, percentage

22.60%

Technology |
Spongecell, Inc.

Schedule of Equity Method Investments [Line Items]

Ownership interest under equity method, percentage

23.00%

Technology |
Transactis

Schedule of Equity Method Investments [Line Items]

Ownership interest under equity method, percentage

24.30%

Technology |
WebLinc

Schedule of Equity Method Investments [Line Items]

Ownership interest under equity method, percentage

38.00%

Operating Segments - Segment Data from Operations (Detail) (USD $)

In Thousands, unless otherwise specified

3 Months Ended

Mar. 31, 2016

Mar. 31, 2015

Dec. 31, 2015

Segment Reporting Information [Line Items]

Operating loss

$ (5,228)

$ (4,880)

Other income (loss), net

0

(388)

Equity income (loss)

(9,495)

(8,662)

Net income (loss)

(15,452)

(14,603)

Segment assets

236,110

256,843

Healthcare

Segment Reporting Information [Line Items]

Operating loss

0

Other income (loss), net

(239)

Equity income (loss)

(4,996)

(4,042)

Net income (loss)

(4,996)

(4,281)

Segment assets

57,351

53,332

Technology

Segment Reporting Information [Line Items]

Operating loss

0

Other income (loss), net

0

Equity income (loss)

(4,500)

(4,772)

Net income (loss)

(4,500)

(4,772)

Segment assets

126,043

119,442

Reportable Subsegments

Segment Reporting Information [Line Items]

Operating loss

0

Other income (loss), net

(239)

Equity income (loss)

(9,496)

(8,814)

Net income (loss)

(9,496)

(9,053)

Segment assets

183,394

172,774

Other Items

Segment Reporting Information [Line Items]

Operating loss

(5,228)

(4,880)

Other income (loss), net

(149)

Equity income (loss)

1

152

Net income (loss)

(5,956)

(5,550)

Segment assets

$ 52,716

$ 84,069

Commitments and Contingencies (Detail) (USD $)

1 Months Ended

Oct. 31, 2001

Mar. 31, 2016

Dec. 31, 2015

Commitment Contingencies And Guarantees [Line Items]

Accrued expenses

$ 3,315,000

$ 2,789,000

Other long-term liabilities

4,030,000

3,965,000

Annual payments

650,000

Employee Severance

Commitment Contingencies And Guarantees [Line Items]

Maximum severance payments

3,000,000

Letter of credit

Commitment Contingencies And Guarantees [Line Items]

Letter of credit under the credit facility

6,300,000

Accrued expenses and other current liabilities

Commitment Contingencies And Guarantees [Line Items]

Liability to former chairman and chief executive officer, current

800,000

Other long-term liabilities

Commitment Contingencies And Guarantees [Line Items]

Liability to former chairman and chief executive officer, non-current

2,200,000

Clawback Liability

Commitment Contingencies And Guarantees [Line Items]

Accrued expenses and other current liabilities

1,300,000

Accrued expenses

1,000,000

Other long-term liabilities

300,000

Company's ownership in the funds

19.00%

Private equity funds

Commitment Contingencies And Guarantees [Line Items]

Company outstanding guarantees

$ 3,800,000

Equity (Details) (USD $)

Share data in Thousands, unless otherwise specified

3 Months Ended

Mar. 31, 2016

Jul. 1, 2015

Equity, Class of Treasury Stock [Line Items]

Stock repurchased during period, value

$ 5,445,000

Common Stock

Equity, Class of Treasury Stock [Line Items]

Stock repurchase program, authorized amount

25,000,000

Repurchase of common stock (in shares)

400

Stock repurchased during period, value

$ 5,400,000

Subsequent Events (Details) (USD $)

3 Months Ended

1 Months Ended

Mar. 31, 2016

Mar. 31, 2015

Apr. 30, 2016

Putney, Inc.

Subsequent Event

Subsequent Event [Line Items]

Proceeds from sales of and distributions from companies

$ 4,194,000

$ 2,192,000

$ 58,200,000

Amount held in escrow

600,000

Gain on sale of business

$ 55,000,000